{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:53:39Z","timestamp":1758448419562,"version":"3.44.0"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jns.2024.122980","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T12:34:15Z","timestamp":1711542855000},"page":"122980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Continuing the search for fluid biomarkers to enhance Huntington's disease staging and therapeutic response"],"prefix":"10.1016","volume":"459","author":[{"given":"Eilrayna","family":"Gelyana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Khamishon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.122980_bb0005","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"7","key":"10.1016\/j.jns.2024.122980_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S1474-4422(22)00120-X","article-title":"A biological classification of Huntington\u2019s disease: the integrated staging system","volume":"21","author":"Tabrizi","year":"2022","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.jns.2024.122980_bb0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","article-title":"Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities","volume":"16","author":"Tabrizi","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"458","key":"10.1016\/j.jns.2024.122980_bb0020","doi-asserted-by":"crossref","first-page":"eaat7108","DOI":"10.1126\/scitranslmed.aat7108","article-title":"Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington\u2019s disease","volume":"10","author":"Byrne","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.jns.2024.122980_bb0025","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","article-title":"Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology","volume":"76","author":"Bridel","year":"2019","journal-title":"JAMA Neurol."},{"issue":"16","key":"10.1016\/j.jns.2024.122980_bb0030","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1001\/jama.289.16.2094","article-title":"Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease","volume":"289","author":"Sunderland","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jns.2024.122980_bb0035","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1212\/01.WNL.0000063313.57292.00","article-title":"Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury","volume":"60","author":"Franz","year":"2003","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.jns.2024.122980_bb0040","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1002\/mds.26668","article-title":"Alzheimer\u2019s disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia","volume":"31","author":"Abdelnour","year":"2016","journal-title":"Mov. Disord."},{"issue":"12","key":"10.1016\/j.jns.2024.122980_bb0045","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.jns.2024.122980_bb0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","article-title":"Blood GFAP as an emerging biomarker in brain and spinal cord disorders","volume":"18","author":"Abdelhak","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jns.2024.122980_bb0055","doi-asserted-by":"crossref","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci Rep."},{"issue":"3","key":"10.1016\/j.jns.2024.122980_bb0060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1212\/WNL.0b013e3181e2414b","article-title":"Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study","volume":"75","author":"Takano","year":"2010","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24001151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:05:39Z","timestamp":1758384339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24001151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":12,"alternative-id":["S0022510X24001151"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.122980","relation":{},"ISSN":["0022-510X"],"issn-type":[{"type":"print","value":"0022-510X"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Continuing the search for fluid biomarkers to enhance Huntington's disease staging and therapeutic response","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.122980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"122980"}}